Literature DB >> 23438125

Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.

Jonathan N King1, Martin Jung, Max P Maurer, Vincent B Schmid, Wolfgang Seewald, Peter Lees.   

Abstract

OBJECTIVE: To establish pharmacokinetics of robenacoxib after administration to cats via the IV, SC, and oral routes. ANIMALS: 24 cats. PROCEDURES: In a crossover design, robenacoxib was administered IV, SC, and orally (experiment 1) and orally (experiment 2) to cats with different feeding regimens. Blood robenacoxib concentrations were assayed, with a lower limit of quantification of 3 ng/mL.
RESULTS: In experiment 1, geometric mean pharmacokinetic values after IV administration of robenacoxib were as follows: blood clearance, 0.44 L/kg/h; plasma clearance, 0.29 L/kg/h; elimination half-life, 1.49 hours; and volume of distribution at steady state (determined from estimated plasma concentrations), 0.13 L/kg. Mean bioavailability was 69% and median time to maximum concentration (Cmax) was 1 hour for cats after SC administration of robenacoxib, whereas mean bioavailability was 49% and 10% and median time to Cmax was 1 hour and 30 minutes after oral administration to cats after food withholding and after cats were fed their entire ration, respectively. In experiment 2, geometric mean Cmax was 1,159, 1,201, and 692 ng/mL and area under the curve from 0 to infinity was 1,337, 1,383, and 1,069 ng × h/mL following oral administration to cats after food withholding, cats fed one-third of the daily ration, and cats fed the entire daily ration, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: For treatment of acute conditions in cats, it is recommended to administer robenacoxib by IV or SC injection, orally after food withholding, or orally with a small amount of food to obtain optimal bioavailability and Cmax.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438125     DOI: 10.2460/ajvr.74.3.465

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial.

Authors:  Cindy Speranza; Vincent Schmid; Jerome M Giraudel; Wolfgang Seewald; Jonathan N King
Journal:  BMC Vet Res       Date:  2015-03-26       Impact factor: 2.741

2.  Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats.

Authors:  L Pelligand; A Soubret; J N King; J Elliott; J P Mochel
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-10-22

Review 3.  Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.

Authors:  Peter Lees; Pierre-Louis Toutain; Jonathan Elliott; Jerome M Giraudel; Ludovic Pelligand; Jonathan N King
Journal:  J Vet Pharmacol Ther       Date:  2022-04-22       Impact factor: 1.567

4.  Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.

Authors:  Jonathan N King; Alessandro Panteri; Melanie Graille; Wolfgang Seewald; Gabriele Friton; Cyril Desevaux
Journal:  BMC Vet Res       Date:  2016-06-23       Impact factor: 2.741

5.  Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats.

Authors:  Mark C Heit; L Jay Stallons; Wolfgang Seewald; Caryn M Thompson; Céline E Toutain; Stephen B King; Rainer Helbig
Journal:  BMC Vet Res       Date:  2020-09-25       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.